Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5126]

Prostate highlights from ECC 2015

Prof Noel Clarke and Dr Bertrand Tombal

Prostate highlights from ECC 2015 ( Prof Noel Clarke and Dr Bertrand Tombal )

EORTC ‘boost no-boost’ trial 20-year follow up: Impact of pathological factors...

Dr Conny Vrieling - Clinique des Grangettes, Geneva, Switzerland

EORTC ‘boost no-boost’ trial 20-year follow up: Impact of pathological factors on long-term local control ( Dr Conny Vrieling - Clinique des Grangettes, Geneva, Switzerland )

Cabozantinib improves advanced kidney cancer survival: METEOR trial results

Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

Cabozantinib improves advanced kidney cancer survival: METEOR trial results ( Prof Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Melanoma immunotherapy latest and TVEC plus pembrolizumab

Dr Georgina Long - University of Sydney, Sydney, Australia

Melanoma immunotherapy latest and TVEC plus pembrolizumab ( Dr Georgina Long - University of Sydney, Sydney, Australia )

Genetic screening of brain metastases could reveal new targets for treatment

Prof Priscilla Brastianos - Massachusetts General Hospital, Boston, USA

Genetic screening of brain metastases could reveal new targets for treatment ( Prof Priscilla Brastianos - Massachusetts General Hospital, Boston, USA )

NETTER-1: Targeted radionuclide therapy improves PFS in mid-gut NETs

Prof Philippe Ruszniewski - Paris Diderot University, Paris, France

NETTER-1: Targeted radionuclide therapy improves PFS in mid-gut NETs ( Prof Philippe Ruszniewski - Paris Diderot University, Paris, France )

RADIANT-4: Results of international trial show promise in the treatment of...

Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA

RADIANT-4: Results of international trial show promise in the treatment of neuroendocrine tumours ( Prof James Yao - University of Texas MD Anderson Cancer Center, Houston, USA )

Mid-gut NETs respond to targeted radionuclide therapy: NETTER-1 results

Prof Philippe Ruszniewski - Paris Diderot University, Paris, France

Mid-gut NETs respond to targeted radionuclide therapy: NETTER-1 results ( Prof Philippe Ruszniewski - Paris Diderot University, Paris, France )

Comment: EUROCARE-5, large blood cancer survival differences throughout Europe

Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium

Comment: EUROCARE-5, large blood cancer survival differences throughout Europe ( Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium )

Comment: New immunotherapy options for kidney cancer

Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium

Comment: New immunotherapy options for kidney cancer ( Prof Martine Piccart - Jules Bordet Institute, Brussels, Belgium )

Tailoring treatment strategies in prostate cancer: expert insight

Prof Eleni Efstathiou, Dr Maria De Santis, Dr Nina Tunariu

Tailoring treatment strategies in prostate cancer: expert insight ( Prof Eleni Efstathiou, Dr Maria De Santis, Dr Nina Tunariu )

Tackling global radiotherapy shortfall could save millions of lives and boost...

Prof Rifat Atun - Harvard University, Boston, USA

Tackling global radiotherapy shortfall could save millions of lives and boost the economy of poorer countries ( Prof Rifat Atun - Harvard University, Boston, USA )

More from ecancer